Onclive » Lung Cancer
154 FOLLOWERS
The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non-small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.
Onclive » Lung Cancer
3w ago
The FDA granted accelerated approval to zenocutuzumab for select patients with NSCLC and pancreatic adenocarcinoma with NRG1 fusions ..read more
Onclive » Lung Cancer
3w ago
Sacituzumab tirumotecan has received breakthrough therapy designation from the FDA for use in select patients with EGFR+ non–small cell lung cancer ..read more
Onclive » Lung Cancer
3w ago
Roy S. Herbst, MD, explores evolving chemoimmunotherapy strategies for early-stage NSCLC that does not harbor actionable mutations ..read more
Onclive » Lung Cancer
3w ago
The FDA has approved durvalumab for adults with limited-stage small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy ..read more
Onclive » Lung Cancer
3w ago
The FDA granted breakthrough therapy designation to Dato-DXd for previously treated EGFR-mutated advanced non–small cell lung cancer ..read more
Onclive » Lung Cancer
3w ago
Savolitinib plus osimertinib received breakthrough therapy designation in China for pretreated, locally advanced or metastatic EGFR-positive NSCLC with MET amplification ..read more
Onclive » Lung Cancer
3w ago
Experts across the fields of lung and GI cancer share key information and insights from 2 recent OncLive biomarker consortiums ..read more
Onclive » Lung Cancer
3w ago
Fixed-duration acalabrutinib combination improves PFS in CLL, imlunestrant ± abemaciclib boosts PFS in ESR1-mutated ER+ breast cancer, and more ..read more
Onclive » Lung Cancer
3w ago
China’s NMPA has approved perioperative pembrolizumab plus chemotherapy for select patients with resectable non–small cell lung cancer ..read more
FDA Approves Companion Diagnostic for Tepotinib in mNSCLC Harboring MET Exon 14 Skipping Alterations
Onclive » Lung Cancer
1M ago
The FDA approved the FoundationOne Liquid CDx to identify patients with mNSCLC with MET exon 14 skipping alterations who may be eligible for tepotinib ..read more